StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs
March 17, 2017 11:05 AM
Goldman Sachs analyst Terence Flynn weighed in on Amgen (NASDAQ: AMGN) after full data from Repatha (PCSK9) Ph3 cardiovascular outcomes ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Amgen (AMGN) FOURIER Results 'Good Enough' - Cowen
March 17, 2017 11:23 AM
Baird Incrementally Negative on Amgen (AMGN) Following FOURIER Data
March 17, 2017 10:40 AM
Amgen (AMGN) call put ratio 1 call to 1.26 puts after reporting Repatha data
March 17, 2017 9:55 AM
Amgen (AMGN) options expected to be active after reporting Repatha data
March 17, 2017 9:31 AM
Medicines Co. (MDCO), Esperion Therapeutics (ESPR) Plunge Following Amgen's (AMGN) Repatha Data
March 17, 2017 9:04 AM
Amgen (AMGN) Says Outcomes Study Shows Repatha Decreases LDL-C to Unprecedented Low Levels, Reduces Risk of Cardiovascular Events
March 17, 2017 9:01 AM
Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
March 17, 2017 9:00 AM
Wall St. flat as banks, Amgen weigh; Adobe rallies
March 17, 2017 7:33 AM
Amgen (AMGN), Peers on Watch Ahead of Repetha Data at ACC.17 (REGN) (ESPR) (MDCO)
March 17, 2017 6:59 AM
Stocks with Implied Volatility Movement
March 17, 2017 5:08 AM
Amgen To Present At The Oppenheimer Global Health Care Conference
March 16, 2017 4:00 PM
_58cbc46cd3c33.jpg)
